NCT00532337View on ClinicalTrials.gov

Controlled Study of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis

PHASE2CompletedINTERVENTIONAL

Enrollment

285

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

July 31, 2010

Conditions

OsteoporosisOsteopenia

Interventions

DRUG

ONO-5334

Placebo - 24/mos.

DRUG

ONO-5334

100mg QD /24 months

DRUG

ONO-5334

50mg BID /24 mos.

DRUG

ONO-5334

300mg QD /24 mos.

DRUG

ONO-5334

Alendronate 70mg once weekly / 24 mos

Trial Locations (1)

Unknown

Andromed Noord Groningen, Damsterdiep 9

Sponsors

Lead Sponsor

Ono Pharma USA Inc

All Listed Sponsors

lead

Ono Pharma USA Inc

INDUSTRY

NCT00532337 - Controlled Study of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis | Biotech Hunter | Biotech Hunter